%PDF-1.6
%
1 0 obj
<>
endobj
2 0 obj
<>stream
Stefanos Aivazidis, Christina M. Coughlan, Abhishek K. Rauniyar, Hua Jiang, L. Alexander Liggett, Kenneth N. Maclean, James R. Roede
The burden of trisomy 21 disrupts the proteostasis network in Down syndrome
www.plosone.org
www.plosone.org
endstream
endobj
3 0 obj
<>/XObject<>>>/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 13 0 R/Annots 14 0 R/Contents 15 0 R/TrimBox[0 0 612 792]>>
endobj
14 0 obj
[16 0 R 17 0 R 18 0 R 19 0 R 20 0 R 21 0 R 22 0 R 23 0 R]
endobj
16 0 obj
<>/Border[0 0 0]/Dest(Rpone.0176307.g001)>>
endobj
17 0 obj
<>/Border[0 0 0]/Dest(Rpone.0176307.ref021)>>
endobj
18 0 obj
<>/Border[0 0 0]/Dest(Rpone.0176307.ref022)>>
endobj
19 0 obj
<>/Border[0 0 0]/Dest(Rpone.0176307.ref023)>>
endobj
20 0 obj
<>/Border[0 0 0]/Dest(Rpone.0176307.ref024)>>
endobj
21 0 obj
<>/Border[0 0 0]/Dest(Rpone.0176307.ref025)>>
endobj
22 0 obj
<>/Border[0 0 0]/Dest(Rpone.0176307.ref026)>>
endobj
23 0 obj
<>/Border[0 0 0]/A 24 0 R>>
endobj
24 0 obj
<>
endobj
15 0 obj
[25 0 R 26 0 R 27 0 R 28 0 R 29 0 R 30 0 R 31 0 R 32 0 R 33 0 R 34 0 R 35 0 R]
endobj
25 0 obj
<>stream
q
0.83 0.64 0.02 0 k
218.5512 654.3496 m
238.1102 654.3496 l
h
f*
374.9102 641.3102 m
384.4346 641.3102 l
h
f*
335.2252 602.3055 m
344.7496 602.3055 l
h
f*
349.1717 602.3055 m
358.6961 602.3055 l
h
f*
381.0331 576.3402 m
390.5575 576.3402 l
h
f*
506.3811 524.2961 m
515.8488 524.2961 l
h
f*
505.5307 198.9354 m
515.0551 198.9354 l
h
f*
0 g
1 j
1 J
0 w
10 0 0 10 211.9748 707.4141 cm
BT
/F6 1 Tf
1 TL
-0.004 Tc
0 0 Td
(Protein)Tj
3.1974 0 Td
(homeostasis,)Tj
5.3121 0 Td
(or)Tj
1.0998 0 Td
(proteostasis,)Tj
5.1477 0 Td
(refers)Tj
2.4605 0 Td
(to)Tj
1.0261 0 Td
(the)Tj
1.4684 0 Td
(correct)Tj
3.0387 0 Td
(function)Tj
3.6283 0 Td
(and)Tj
1.7291 0 Td
(balanced)Tj
3.7644 0 Td
(abundance)Tj
-33.0687 -1.3039 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.4683 0 Td
(cellular)Tj
3.1407 0 Td
(proteome.)Tj
4.3087 0 Td
(The)Tj
1.7858 0 Td
(proteostasis)Tj
4.9266 0 Td
(network)Tj
3.5489 0 Td
(\(PN\))Tj
2.194 0 Td
(is)Tj
0.8504 0 Td
(the)Tj
1.4684 0 Td
(system)Tj
2.9366 0 Td
(responsible)Tj
4.7565 0 Td
(for)Tj
1.3833 0 Td
(main-)Tj
-33.783 -1.2982 Td
(taining)Tj
3.05 0 Td
(the)Tj
1.4683 0 Td
(stability)Tj
3.3506 0 Td
(and)Tj
1.7348 0 Td
(integrity)Tj
3.6113 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.4683 0 Td
(proteome.)Tj
4.3143 0 Td
(Synthesis)Tj
3.9401 0 Td
(of)Tj
1.0148 0 Td
(proteins,)Tj
3.7361 0 Td
(as)Tj
1.0148 0 Td
(well)Tj
1.8198 0 Td
(as)Tj
1.0148 0 Td
(proper)Tj
2.931 0 Td
(pro-)Tj
-35.4838 -1.2983 Td
(tein)Tj
1.7574 0 Td
(folding,)Tj
3.2938 0 Td
(repair/disaggregation,)Tj
8.9972 0 Td
(and)Tj
1.7291 0 Td
(clearance/degradation)Tj
9.0821 0 Td
(are)Tj
1.4457 0 Td
(major)Tj
2.6078 0 Td
(components)Tj
5.1761 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
-35.104 -1.2983 Td
(PN)Tj
1.5136 0 Td
(\()Tj
0.83 0.64 0.02 0 k
(Fig)Tj
1.8199 0 Td
(1)Tj
0 g
(\).)Tj
1.2642 0 Td
(The)Tj
1.7801 0 Td
(PN)Tj
1.5137 0 Td
(includes)Tj
3.549 0 Td
(the)Tj
1.4683 0 Td
(ribosome,)Tj
4.2066 0 Td
(molecular)Tj
4.2179 0 Td
(chaperones,)Tj
4.9833 0 Td
(and)Tj
1.7291 0 Td
(degradation)Tj
5.0287 0 Td
(machinery)Tj
-33.0744 -1.3039 Td
(involved)Tj
3.6509 0 Td
(in)Tj
1.0318 0 Td
(the)Tj
1.4684 0 Td
(proteasome)Tj
4.8869 0 Td
(and)Tj
1.7291 0 Td
(autophagy)Tj
4.3823 0 Td
([)Tj
0.83 0.64 0.02 0 k
(21)Tj
0 g
(].)Tj
2.0807 0 Td
(In)Tj
1.1055 0 Td
(addition,)Tj
3.8267 0 Td
(there)Tj
2.262 0 Td
(are)Tj
1.4514 0 Td
(several)Tj
2.931 0 Td
(PN)Tj
1.5137 0 Td
(modulators,)Tj
-32.3204 -1.2982 Td
(like)Tj
1.6497 0 Td
(the)Tj
1.474 0 Td
(unfolded)Tj
3.8154 0 Td
(protein)Tj
3.1521 0 Td
(response)Tj
3.7304 0 Td
(\(UPR\))Tj
2.8176 0 Td
(and)Tj
1.7348 0 Td
(the)Tj
1.4683 0 Td
(transcription)Tj
5.4312 0 Td
(factor)Tj
2.5455 0 Td
(heat)Tj
1.8992 0 Td
(shock)Tj
2.5398 0 Td
(factor-1)Tj
-32.258 -1.2983 Td
(\(HSF-1\),)Tj
3.719 0 Td
(that)Tj
1.7801 0 Td
(modify)Tj
3.0841 0 Td
(the)Tj
1.4683 0 Td
(PN,)Tj
1.7405 0 Td
(and)Tj
1.7348 0 Td
(disruption)Tj
4.4107 0 Td
(or)Tj
1.0998 0 Td
(alteration)Tj
4.0478 0 Td
(of)Tj
1.0148 0 Td
(these)Tj
2.2507 0 Td
(modulators)Tj
4.8246 0 Td
(can)Tj
1.6214 0 Td
(lead)Tj
1.8538 0 Td
(to)Tj
1.0262 0 Td
(the)Tj
-35.6766 -1.3039 Td
(distortion)Tj
4.1725 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.4683 0 Td
(PN)Tj
1.5137 0 Td
(architecture)Tj
5.0117 0 Td
([)Tj
0.83 0.64 0.02 0 k
(22)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
1.7347 0 Td
(23)Tj
0 g
(].)Tj
1.7405 0 Td
(Finally,)Tj
3.1691 0 Td
(malfunction)Tj
5.1307 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.4683 0 Td
(PN)Tj
1.5137 0 Td
(has)Tj
1.5421 0 Td
(been)Tj
2.1259 0 Td
(proposed)Tj
3.9515 0 Td
(as)Tj
-36.5723 -1.2983 Td
(an)Tj
1.2018 0 Td
(etiologic)Tj
3.6227 0 Td
(factor)Tj
2.5455 0 Td
(for)Tj
1.3833 0 Td
(the)Tj
1.4683 0 Td
(promotion)Tj
4.5638 0 Td
(of)Tj
1.0148 0 Td
(certain)Tj
2.9877 0 Td
(diseases,)Tj
3.6056 0 Td
(as)Tj
1.0148 0 Td
(PN)Tj
1.5137 0 Td
(imbalance)Tj
4.3256 0 Td
(leads)Tj
2.211 0 Td
(to)Tj
1.0262 0 Td
(misfolded)Tj
-32.4848 -1.2983 Td
(protein)Tj
3.152 0 Td
(accumulation)Tj
5.675 0 Td
(and)Tj
1.7348 0 Td
(proteotoxic)Tj
4.8018 0 Td
(stress)Tj
2.3981 0 Td
([)Tj
0.83 0.64 0.02 0 k
(24)Tj
0 g
(].)Tj
-16.5655 -1.3039 Td
(Since)Tj
2.3584 0 Td
(alterations)Tj
4.4106 0 Td
(in)Tj
1.0375 0 Td
(the)Tj
1.4684 0 Td
(PN)Tj
1.5136 0 Td
(occur)Tj
2.4775 0 Td
(in)Tj
1.0318 0 Td
(various)Tj
3.1464 0 Td
(pathological)Tj
5.091 0 Td
(conditions,)Tj
4.6999 0 Td
(e.g.)Tj
1.559 0 Td
(diabetes,)Tj
3.6907 0 Td
(AD,)Tj
-33.681 -1.2982 Td
(vision-related)Tj
5.6919 0 Td
(defects,)Tj
3.1861 0 Td
(thyroid)Tj
3.1691 0 Td
(dysfunction,)Tj
5.193 0 Td
(and)Tj
1.7235 0 Td
(epilepsy,)Tj
3.651 0 Td
(we)Tj
1.3209 0 Td
(hypothesized)Tj
5.4595 0 Td
(that,)Tj
2.0013 0 Td
(due)Tj
1.6894 0 Td
(to)Tj
1.0205 0 Td
(the)Tj
1.4626 0 Td
(pres-)Tj
-35.5688 -1.2983 Td
(ence)Tj
2.0352 0 Td
(of)Tj
1.0148 0 Td
(these)Tj
2.2564 0 Td
(comorbidities)Tj
5.7656 0 Td
(in)Tj
1.0375 0 Td
(the)Tj
1.4683 0 Td
(DS)Tj
1.4343 0 Td
(population,)Tj
4.8132 0 Td
(cells)Tj
1.9219 0 Td
(from)Tj
2.2053 0 Td
(DS)Tj
1.4344 0 Td
(individuals)Tj
4.6488 0 Td
(will)Tj
1.661 0 Td
(display)Tj
3.0274 0 Td
(a)Tj
0.6577 0 Td
(dys-)Tj
-35.3818 -1.3039 Td
(functional)Tj
4.3086 0 Td
(PN.)Tj
1.7404 0 Td
(Also,)Tj
2.2451 0 Td
(the)Tj
1.4683 0 Td
(burden)Tj
3.1238 0 Td
(of)Tj
1.0148 0 Td
(trisomy,)Tj
3.5262 0 Td
(mediated)Tj
3.9402 0 Td
(by)Tj
1.1848 0 Td
(gene)Tj
2.0807 0 Td
(dosage)Tj
2.9366 0 Td
(effects)Tj
2.7269 0 Td
([)Tj
0.83 0.64 0.02 0 k
(25)Tj
0 g
(],)Tj
2.075 0 Td
(has)Tj
1.542 0 Td
(the)Tj
-33.9134 -1.2983 Td
(potential)Tj
3.7587 0 Td
(to)Tj
1.0261 0 Td
(disturb)Tj
3.0784 0 Td
(proteostasis)Tj
4.9266 0 Td
(by)Tj
1.1849 0 Td
(overwhelming)Tj
5.9583 0 Td
(the)Tj
1.4684 0 Td
(cellular)Tj
3.1407 0 Td
(translational)Tj
5.2101 0 Td
(quality)Tj
2.9593 0 Td
(control)Tj
-32.7115 -1.2982 Td
(mechanisms,)Tj
5.4311 0 Td
(that)Tj
1.7745 0 Td
(over)Tj
1.9785 0 Td
(time)Tj
2.0296 0 Td
(would)Tj
2.7099 0 Td
(act)Tj
1.3777 0 Td
(as)Tj
1.0148 0 Td
(a)Tj
0.6519 0 Td
(mechanism)Tj
4.8472 0 Td
(to)Tj
1.0262 0 Td
(promote)Tj
3.6623 0 Td
(disease)Tj
3.0161 0 Td
(pathology)Tj
4.1782 0 Td
(and)Tj
-33.698 -1.2983 Td
(decrease)Tj
3.6056 0 Td
(cell)Tj
1.559 0 Td
(viability.)Tj
3.6454 0 Td
(Consistent)Tj
4.4957 0 Td
(with)Tj
1.9956 0 Td
(our)Tj
1.627 0 Td
(hypothesis,)Tj
4.6885 0 Td
(we)Tj
1.3266 0 Td
(observed)Tj
3.7984 0 Td
(several)Tj
2.931 0 Td
(components)Tj
5.1761 0 Td
(of)Tj
1.0147 0 Td
(the)Tj
-35.8636 -1.3039 Td
(protein)Tj
3.152 0 Td
(quality)Tj
2.9537 0 Td
(control)Tj
3.1238 0 Td
(machinery)Tj
4.49 0 Td
(in)Tj
1.0375 0 Td
(DS)Tj
1.4287 0 Td
(cell)Tj
1.559 0 Td
(models)Tj
3.1068 0 Td
(to)Tj
1.0261 0 Td
(be)Tj
1.1509 0 Td
(dysfunctional)Tj
5.6522 0 Td
(compared)Tj
4.2406 0 Td
(to)Tj
1.0261 0 Td
(euploid)Tj
-33.9474 -1.2983 Td
(controls.)Tj
3.7076 0 Td
(Furthermore,)Tj
5.6126 0 Td
(treatment)Tj
4.1385 0 Td
(with)Tj
1.9956 0 Td
(stressors)Tj
3.634 0 Td
(that)Tj
1.7802 0 Td
(disrupt)Tj
3.0897 0 Td
(the)Tj
1.4683 0 Td
(PN)Tj
1.5194 0 Td
(resulted)Tj
3.3959 0 Td
(in)Tj
1.0375 0 Td
(decreased)Tj
4.1329 0 Td
(cell)Tj
-35.5122 -1.2983 Td
(viability)Tj
3.4128 0 Td
(in)Tj
1.0375 0 Td
(DS)Tj
1.4343 0 Td
(cells)Tj
1.9162 0 Td
(compared)Tj
4.2463 0 Td
(to)Tj
1.0261 0 Td
(controls.)Tj
3.7077 0 Td
(Our)Tj
1.8652 0 Td
(basic)Tj
2.211 0 Td
(findings)Tj
3.4923 0 Td
(from)Tj
2.2053 0 Td
(this)Tj
1.6781 0 Td
(characterization)Tj
6.6614 0 Td
(sug-)Tj
-34.8942 -1.3039 Td
(gest)Tj
1.7687 0 Td
(that)Tj
1.7745 0 Td
(therapeutic)Tj
4.7339 0 Td
(strategies,)Tj
4.1498 0 Td
(designed)Tj
3.7644 0 Td
(to)Tj
1.0262 0 Td
(alleviate)Tj
3.4469 0 Td
(dysfunction)Tj
4.9719 0 Td
(of)Tj
1.0148 0 Td
(the)Tj
1.4683 0 Td
(PN,)Tj
1.7405 0 Td
(will)Tj
1.6668 0 Td
(promote)Tj
3.6623 0 Td
(clear-)Tj
-35.189 -1.2982 Td
(ance)Tj
2.0465 0 Td
(of)Tj
1.0148 0 Td
(misfolded)Tj
4.1896 0 Td
(proteins,)Tj
3.7417 0 Td
(potentially)Tj
4.4617 0 Td
(resulting)Tj
3.7247 0 Td
(in)Tj
1.0375 0 Td
(significant)Tj
4.388 0 Td
(therapeutic)Tj
4.7338 0 Td
(outcomes)Tj
4.0876 0 Td
(in)Tj
1.0318 0 Td
(the)Tj
1.474 0 Td
(DS)Tj
-35.9317 -1.2983 Td
(population.)Tj
ET
Q
q
1 j
1 J
0 w
11.9999 0 0 11.9999 200.0125 382.2236 cm
BT
/F2 1 Tf
1 TL
-0.0033 Tc
0 0 Td
(Materials)Tj
4.5071 0 Td
(and)Tj
1.989 0 Td
(methods)Tj
/F0 1 Tf
-6.4961 -1.5023 Td
(Reagents)Tj
4.4504 0 Td
(and)Tj
1.8614 0 Td
(antibodies)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 200.0125 347.1874 cm
BT
/F6 1 Tf
1 TL
-0.004 Tc
0 0 Td
(Maneb)Tj
3.0217 0 Td
(\(Product)Tj
3.7757 0 Td
(number)Tj
3.4185 0 Td
(45554\))Tj
2.9367 0 Td
(and)Tj
1.7348 0 Td
(tunicamycin)Tj
5.2327 0 Td
(\(Product)Tj
3.7701 0 Td
(number)Tj
3.4186 0 Td
(T7765\))Tj
3.0784 0 Td
(were)Tj
2.1203 0 Td
(purchased)Tj
-32.5075 -1.2982 Td
(from)Tj
2.2053 0 Td
(Sigma-Aldrich.)Tj
6.3042 0 Td
(4)Tj
/F11 1 Tf
[()]TJ
/F6 1 Tf
(8c)Tj
2.1033 0 Td
(\(Product)Tj
3.7757 0 Td
(number)Tj
3.4129 0 Td
(412512\))Tj
3.4186 0 Td
(was)Tj
1.6951 0 Td
(purchased)Tj
4.337 0 Td
(from)Tj
2.2053 0 Td
(EMD)Tj
2.4151 0 Td
(Millipore.)Tj
4.1839 0 Td
(All)Tj
-36.0564 -1.2983 Td
(other)Tj
2.347 0 Td
(reagents)Tj
3.5433 0 Td
(were)Tj
2.126 0 Td
(purchased)Tj
4.3313 0 Td
(from)Tj
2.2053 0 Td
(Fisher-Scientific.)Tj
6.9562 0 Td
(The)Tj
1.7858 0 Td
(following)Tj
3.9798 0 Td
(primary)Tj
3.4526 0 Td
(antibodies)Tj
4.3597 0 Td
(were)Tj
-35.087 -1.3039 Td
(purchased)Tj
4.3313 0 Td
(from)Tj
2.2053 0 Td
(Cell)Tj
1.8028 0 Td
(Signaling)Tj
3.9345 0 Td
(Technology:)Tj
5.159 0 Td
(XBP1s)Tj
2.8516 0 Td
(\(D2C1F\))Tj
3.7758 0 Td
(\(12782\),)Tj
3.5036 0 Td
(ubiquitin)Tj
3.9401 0 Td
(\(3933\),)Tj
3.0274 0 Td
(phos-)Tj
-34.5314 -1.2983 Td
(pho-eIF2)Tj
/F12 1 Tf
()Tj
/F6 1 Tf
4.456 0 Td
(\(Ser51\))Tj
3.1237 0 Td
(\(9721\),)Tj
3.0274 0 Td
(eIF2)Tj
/F12 1 Tf
()Tj
/F6 1 Tf
2.5569 0 Td
(\(9722\),)Tj
3.0273 0 Td
(IRE1)Tj
/F12 1 Tf
()Tj
/F6 1 Tf
2.795 0 Td
(\(3294\),)Tj
3.0274 0 Td
(HSP40)Tj
2.9763 0 Td
(\(4871\),)Tj
3.0274 0 Td
(HSP70)Tj
2.9707 0 Td
(\(4872\),)Tj
3.0331 0 Td
(HSP90)Tj
-34.0212 -1.2982 Td
(\(4877\).)Tj
3.0273 0 Td
(The)Tj
1.7802 0 Td
(following)Tj
3.9798 0 Td
(primary)Tj
3.4582 0 Td
(antibodies)Tj
4.3597 0 Td
(were)Tj
2.1203 0 Td
(purchased)Tj
4.337 0 Td
(from)Tj
2.2053 0 Td
(Abcam:)Tj
3.3109 0 Td
(ATF6)Tj
2.5228 0 Td
(\(ab122897\),)Tj
4.9152 0 Td
(and)Tj
-36.0167 -1.3039 Td
(XBP1)Tj
2.4888 0 Td
(\(ab37152\).)Tj
4.439 0 Td
(The)Tj
1.7858 0 Td
(primary)Tj
3.4526 0 Td
(antibody)Tj
3.7644 0 Td
(against)Tj
3.0273 0 Td
(phospho-IRE1)Tj
/F12 1 Tf
()Tj
/F6 1 Tf
6.6161 0 Td
(\(Ser724\))Tj
3.5943 0 Td
(was)Tj
1.7007 0 Td
(purchased)Tj
4.3314 0 Td
(from)Tj
-35.2004 -1.2983 Td
(Novus)Tj
2.8062 0 Td
(Biologicals.)Tj
4.7509 0 Td
(The)Tj
1.7801 0 Td
(primary)Tj
3.4526 0 Td
(antibody)Tj
3.7644 0 Td
(against)Tj
3.033 0 Td
(HSP27)Tj
2.9707 0 Td
(was)Tj
1.7008 0 Td
(purchased)Tj
4.3313 0 Td
(by)Tj
1.1849 0 Td
(Enzo)Tj
2.2563 0 Td
(Life)Tj
1.7348 0 Td
(Sciences)Tj
-33.766 -1.2983 Td
(\(G3.1\).)Tj
3.016 0 Td
(The)Tj
1.7801 0 Td
(primary)Tj
3.4583 0 Td
(antibody)Tj
3.7644 0 Td
(against)Tj
/F12 1 Tf
3.0274 0 Td
()Tj
/F6 1 Tf
(-actin)Tj
3.0273 0 Td
(\(A5441\))Tj
3.4866 0 Td
(was)Tj
1.7008 0 Td
(purchased)Tj
4.3313 0 Td
(from)Tj
2.2054 0 Td
(Sigma-Aldrich.)Tj
ET
Q
q
1 j
1 J
0 w
11.9999 0 0 11.9999 200.0125 217.0204 cm
BT
/F0 1 Tf
1 TL
-0.0033 Tc
0 0 Td
(Cell)Tj
1.9134 0 Td
(culture)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 200.0125 200.0125 cm
BT
/F6 1 Tf
1 TL
-0.004 Tc
0 0 Td
(Lymphoblastoid)Tj
6.7294 0 Td
(cell)Tj
1.559 0 Td
(lines)Tj
2.0693 0 Td
(\(LCL\),)Tj
2.863 0 Td
(immortalized)Tj
5.6182 0 Td
(using)Tj
2.3867 0 Td
(the)Tj
1.4684 0 Td
(Epstein-Barr)Tj
5.3121 0 Td
(virus)Tj
2.2053 0 Td
([)Tj
0.83 0.64 0.02 0 k
(26)Tj
0 g
(],)Tj
2.075 0 Td
(were)Tj
-32.2864 -1.3039 Td
(obtained)Tj
3.7303 0 Td
(from)Tj
2.2054 0 Td
(the)Tj
1.474 0 Td
(Intellectual)Tj
4.6714 0 Td
(and)Tj
1.7348 0 Td
(Developmental)Tj
6.2986 0 Td
(Disabilities)Tj
4.6544 0 Td
(Research)Tj
3.8041 0 Td
(Center)Tj
2.948 0 Td
(\(IDDRC\))Tj
-31.521 -1.2982 Td
(Nexus)Tj
2.7325 0 Td
(\(Colorado)Tj
4.3257 0 Td
(Multiple)Tj
3.634 0 Td
(Institutional)Tj
5.1647 0 Td
(Review)Tj
3.0954 0 Td
(Board)Tj
2.6418 0 Td
(\(COMIRB\))Tj
4.7395 0 Td
(#081276\))Tj
4.4107 0 Td
(in)Tj
1.0318 0 Td
(the)Tj
1.474 0 Td
(Depart-)Tj
-33.2501 -1.2983 Td
(ment)Tj
2.3073 0 Td
(of)Tj
1.0148 0 Td
(Pediatrics)Tj
4.1556 0 Td
(at)Tj
0.9524 0 Td
(the)Tj
1.4684 0 Td
(University)Tj
4.405 0 Td
(of)Tj
1.0148 0 Td
(Colorado)Tj
3.9798 0 Td
(Anschutz)Tj
4.0025 0 Td
(Medical)Tj
3.4356 0 Td
(Campus.)Tj
3.77 0 Td
(LCLs)Tj
2.3187 0 Td
(from)Tj
2.2054 0 Td
(three)Tj
-35.0303 -1.2983 Td
(DS)Tj
1.4286 0 Td
(patients)Tj
3.3675 0 Td
(were)Tj
2.126 0 Td
(used)Tj
2.058 0 Td
(\(female,)Tj
3.4185 0 Td
(18.4)Tj
1.8765 0 Td
(yrs)Tj
1.406 0 Td
(old;)Tj
1.7235 0 Td
(male,)Tj
2.3697 0 Td
(18.3)Tj
1.8709 0 Td
(yrs)Tj
1.4116 0 Td
(old;)Tj
1.7235 0 Td
(female,)Tj
3.0784 0 Td
(7.9)Tj
1.4003 0 Td
(yrs)Tj
1.406 0 Td
(old\))Tj
1.8425 0 Td
(and)Tj
1.7291 0 Td
(three)Tj
-34.2366 -1.3039 Td
(non-DS,)Tj
3.6113 0 Td
(age-matched)Tj
5.3461 0 Td
(controls)Tj
3.4809 0 Td
(were)Tj
2.126 0 Td
(used)Tj
2.0579 0 Td
(as)Tj
1.0148 0 Td
(euploid)Tj
3.2371 0 Td
(controls)Tj
3.481 0 Td
(\(CTL\))Tj
2.7155 0 Td
(\(female,)Tj
3.4186 0 Td
(17.9)Tj
1.8709 0 Td
(yrs)Tj
1.4116 0 Td
(old;)Tj
-33.7717 -1.2982 Td
(male,)Tj
2.3697 0 Td
(16.4)Tj
1.8709 0 Td
(yrs)Tj
1.4059 0 Td
(old;)Tj
1.7292 0 Td
(female,)Tj
3.0784 0 Td
(7.5)Tj
1.3946 0 Td
(yrs)Tj
1.406 0 Td
(old\).)Tj
2.0692 0 Td
(The)Tj
1.7802 0 Td
(LCLs)Tj
2.3244 0 Td
(were)Tj
2.1203 0 Td
(cultured)Tj
3.566 0 Td
(in)Tj
1.0374 0 Td
(RPMI)Tj
2.6306 0 Td
(1640)Tj
2.1259 0 Td
(medium)Tj
3.6057 0 Td
(con-)Tj
-34.5144 -1.2983 Td
(taining)Tj
3.05 0 Td
(L-glutamine,)Tj
5.3631 0 Td
(15%)Tj
1.9276 0 Td
(FBS,)Tj
2.0296 0 Td
(and)Tj
1.7291 0 Td
(1%)Tj
1.4513 0 Td
(antibiotic/antimycotic)Tj
9.1105 0 Td
(solution.)Tj
3.7077 0 Td
(For)Tj
1.6271 0 Td
(mechanistic)Tj
5.0116 0 Td
(stud-)Tj
-35.0076 -1.3039 Td
(ies,)Tj
1.4966 0 Td
(we)Tj
1.3266 0 Td
(utilized)Tj
3.1918 0 Td
(human)Tj
3.0784 0 Td
(fibroblasts)Tj
4.3654 0 Td
(derived)Tj
3.2144 0 Td
(from)Tj
2.2054 0 Td
(the)Tj
1.474 0 Td
(foreskin)Tj
3.4809 0 Td
(of)Tj
1.0148 0 Td
(DS)Tj
1.4343 0 Td
(and)Tj
1.7291 0 Td
(euploid)Tj
3.2372 0 Td
(patients.)Tj
-31.2489 -1.2983 Td
(Detroit)Tj
3.118 0 Td
(551)Tj
1.6498 0 Td
(\(CCL-110\),)Tj
4.7678 0 Td
(a)Tj
0.652 0 Td
(disomic)Tj
3.3959 0 Td
(cell)Tj
1.559 0 Td
(line)Tj
1.7065 0 Td
(used)Tj
2.0579 0 Td
(as)Tj
1.0148 0 Td
(euploid)Tj
3.2372 0 Td
(control)Tj
3.1237 0 Td
(\(CTL\))Tj
2.7099 0 Td
(in)Tj
1.0375 0 Td
(our)Tj
1.6271 0 Td
(experiments,)Tj
ET
Q
q
1 j
1 J
0 w
576 737.1 m
36 737.1 l
36 737.6 l
576 737.6 l
f*
36 741.2598 107.1496 23.6976 re
W* n
q
107.0929 0 0 23.6409 36 741.3165 cm
q
/I0 Do
Q
Q
Q
q
0 0 612 792 re
W* n
1 j
1 J
0 w
7.9999 0 0 7.9999 415.8992 745.7952 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(The)Tj
1.9134 0 Td
(proteostasi)Tj
4.8047 0 Td
(s)Tj
0.7158 0 Td
(network)Tj
3.6638 0 Td
(and)Tj
1.8567 0 Td
(Down)Tj
2.7354 0 Td
(syndrom)Tj
3.7701 0 Td
(e)Tj
ET
Q
q
1 j
1 J
0 w
36 48.0002 m
576 48.0002 l
576 47.5002 l
36 47.5002 l
f*
0.83 0.64 0.02 0 k
81.5811 34.9228 m
237.8835 34.9228 l
h
f*
0 g
7.9999 0 0 7.9999 36 36 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(PLOS)Tj
2.8559 0 Td
(ONE)Tj
2.3669 0 Td
(|)Tj
0.83 0.64 0.02 0 k
0.4748 0 Td
(https://doi.or)Tj
5.4142 0 Td
(g/10.137)Tj
3.8198 0 Td
(1/journal.po)Tj
5.1236 0 Td
(ne.01763)Tj
4.089 0 Td
(07)Tj
0 g
2.0906 0 Td
(April)Tj
2.1827 0 Td
(21,)Tj
1.5874 0 Td
(2017)Tj
35.1357 0 Td
(2)Tj
0.7654 0 Td
(/)Tj
0.496 0 Td
(22)Tj
/F9 1 Tf
-0.025 Tc
-66.402 84.0904 Td
(laboratory)Tj
3.9685 0 Td
(start-up)Tj
3.1323 0 Td
(were)Tj
2.0126 0 Td
(used)Tj
2.0055 0 Td
(to)Tj
0.9496 0 Td
(support)Tj
3.0969 0 Td
(a)Tj
0.6449 0 Td
(majority)Tj
-15.8103 -1.3748 Td
(of)Tj
0.9496 0 Td
(this)Tj
1.559 0 Td
(work.)Tj
/F8 1 Tf
-2.5086 -2.126 Td
(Competing)Tj
4.3795 0 Td
(interests)Tj
3.3307 0 Td
(:)Tj
/F9 1 Tf
0.4819 0 Td
(The)Tj
1.5875 0 Td
(authors)Tj
3.0401 0 Td
(have)Tj
1.963 0 Td
(declared)Tj
-14.7827 -1.3749 Td
(that)Tj
1.6228 0 Td
(no)Tj
1.1693 0 Td
(competing)Tj
4.1599 0 Td
(interests)Tj
ET
endstream
endobj
26 0 obj
<>stream
endstream
endobj
27 0 obj
<>stream
endstream
endobj
28 0 obj
<>stream
endstream
endobj
29 0 obj
<>stream
endstream
endobj
30 0 obj
<>stream
endstream
endobj
31 0 obj
<>stream
endstream
endobj
32 0 obj
<>stream
endstream
endobj
33 0 obj
<>stream
endstream
endobj
34 0 obj
<>stream
endstream
endobj
35 0 obj
<>stream
BT
10.3394 79.2147 Td
(exist.)Tj
ET
Q
endstream
endobj
36 0 obj
<>/XObject<>>>/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 13 0 R/Annots 38 0 R/Contents 39 0 R/TrimBox[0 0 612 792]>>
endobj
37 0 obj
<>stream
xlյߛ\'@pw8!݃@8rp BH3ݣh=S{Zϒ:c3M$ H@ '/:ye{8nJe$ H@$ H@$ H@$ 'BEEF)Ow`xxx#^=^{W㥗wj%Vސ;swO,E,GYxPhQng$ H@$ H@$ H@$ '\%A5qA/SEEE~xxxxӟ⮻bȸƸꪸ8888888=4C}&;=_:v=v5v%vc3n83ٹk'oyCnyD#㏏NOΊr^vY\qE\{m?-ĝwfǓOsŨQ)y#m#d#D*T+lx|e=J@$ H@$ H@$ H@@g\#]l;*'Z''_cQ}6x衸ԅVX;/N;-;._=_"60Z+V[-VX!^:]4X f駏&I&&4?/7';+3#F=~G-~я;N9)-efTvTRe*N' &0
I')ig9y獅%喋UV5ֈM6-_*usTrdqtOώ/..n)#GRF⏉6^r47:R7()ݥR$ H@$ H@$ H@@MHȈLg̳h ]lMBP~c|q=)V,]b1ϋ/allĚk+20<:,1t11)"֯sfH익B"ڢ\\TlvҎ]QuK~w]q|NtC|(=(a/VmK
{!:;K"{3
EgQ6fYg9fXxڱƱ喹N 7nK.I6s4LSOSS&9A_r9xg6M$ H@$ H@$ H@X!4ceJJbh]A]
#:#j#N;[iE\~Xrɔ)/%gLE.&]ꡈ}UQZPc/:/^n4ӤrN:LR)EPW̲z묓ߍ6M77O5ve] 7T
6Q&lc Lnڄ&v'ȎeSM mv@u9NoN4*ܐrsz!M@o^Dvm_26K3>M(L+j*ŗ]6΅?\1)"ML9e?yi oΨ0<*v=-ES"[}srZ Nbb';~v#^S)*HrK/MG72d맟N<X@^lDjC:BUz`M/V$ H@$ H@$ H`@+̸ \Xq19EdLEd,$& 6QH_Qc;j7 Y1ɢW)?wՔK"2]D>.ctB8&vgٚGdtRBE1CDr0\TFEh$M&w4+;&;[S@G$o2mNxrI-3s.VZtzB.'t0$8;b=;9QH?/:~A^U{qܜx-)faHW_̈́ 6'5Hls|趬 C}e;OW_tLʄF=đ1#u4=6Q 4
MC-`1@G&7?r36K
BFtAt:xIg|
TMS#Ь暬jjJѩ D lM3pcW3U$ H@$ H@$ H@cؙ&5MSJItoȎlS02⋧[Wх"-qŖ)HEzb|`w'2w^ikooۈx)gLXLUX =jT*%u"ע9Z0.
o!? ,;Zdq%aȎ^نeQ/Uڱ*[j8jA
FtvܒލU%FiPY̺Yg7f,t3|$on@gKqu.tj1IየE*tC7AaZ<ŜBt']t-xЗ3tI@$ H@$ H@$ H`h@vDmDaDUDFD@9\DuMb(Jgt@XYP\_F5F;_.逈&1U8^OT($wƬy}UQ$qy+Q.5FՋHE
*vȂ\[C{ub/NҍMDEԦq1#a_ 2 ! _^^Rf|3(:A[#{:}Գh(HҵÃ ^ZHw7j"#3d3XKѿԈI#D-lo% H@$ H@$ H@$ V@B#315cIpوwȾؙ~)Ff:¼Lk#"a܌Ӑ Čn3u2jyemHgLv&5")2"5T~WX ČvY8yUZO>ڀR5j5)qaa|͚:]DwS)-Ng
215 ^2ԨG&5ݾ̳_,@pMgP RЩ1es9m%35 N>!Qx$ H@$ H@$ H@$SMf7nQ& /1.fev6v5Tb/ѭPFmnB nƅzBBCHF
D&83V%$"RcןO#34!N B' 0k ث8{ӞOUR\F& ѼITM fbgL1>DGϐ!8O>9ׁ Lc&-)[\ߒH@$ H@$ H@$ %$VL]|g^OX~><rQJ2ː
鹐Уw'N.d=ĸԲ0,^p+#.98Li$0 01\Nc^>!;&C/TĜuD 7"5ÊWZ<@^u|\/N6A0PSJE(!{1'4KDY$ H@$ H@$ H I`_&0Mt(!辄&51W.D./:rR~L$fi3瘣meFzUMdl$0@@&$8Ѧ0O$ q:vXglmlI0"9NY1 htV̚'fH5ײ!8hOtqB MfQ
auJIf2q$ H@$ H@$ H@U)rK\~y*ɪ馱ZʙsetAsf.XZe2| s_3vNf|sh18@IČFp7KUE{E
f0@)FM)W5{/p{qMod2;@{8d)R}Lґ
VdRfI)4Qӷߞ4 I@$ H@$ H@$ VUFBBnF!½H]$*